Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Kanzhun Insider Sold Shares Worth $6,118,209, According to a Recent SEC Filing

Kanzhun Insider Sold Shares Worth $6,118,209, According to a Recent SEC Filing

MT newswireMT newswire2026/09/14 20:13
04:13 PM EDT, 09/14/2026 (MT Newswires) -- Peng Jonathan Zhao, 10% Owner, Director, Chief Executive Officer, on September 10, 2026, sold 743,600 shares in Kanzhun (BZ) for $6,118,209. Following the Form 4 filing with the SEC, Zhao has control over a total of 2,824,080 Class A ordinary shares of the company, with 2,824,080 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1842827/000110465926107486/xslF345X05/tm2625370-1_4seq1.xml
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage